Preventive Health
Annual Liver and Digestive Health Checklist
A practical, evidence-based annual checklist covering the tests, screenings, and lifestyle checks most likely to detect liver and digestive problems early — before symptoms appear.
Most liver and digestive diseases are silent in their early stages — they cause no symptoms until damage is already extensive. This means that waiting for symptoms to prompt a doctor’s visit is the wrong strategy for these organ systems. Annual health checks, structured screening intervals, and proactive monitoring of known risk factors give liver and digestive conditions the best chance of being caught early, when treatment options are most effective and outcomes are best.
This annual checklist is designed for adults aged 40 and older. It consolidates the recommended checks, tests, and lifestyle assessments across liver health, colorectal cancer screening, upper GI surveillance, and digestive function into a single practical framework. Not every item applies to every person — the checklist is structured to help you identify which items are relevant to your individual risk profile.
Section 1: Blood Tests — What to Check and When
Annual blood work is the most accessible tool for monitoring liver and metabolic health. The following tests are relevant for most adults over 40, with additional tests applicable based on individual risk factors:
Liver enzymes (ALT, AST, ALP, GGT): These four enzymes reflect different aspects of liver health. ALT and AST elevations suggest hepatocyte (liver cell) injury. ALP and GGT elevations can indicate bile duct disease, medication effects, or bone disease. In adults with NAFLD risk factors (obesity, metabolic syndrome, type 2 diabetes), annual liver enzyme testing helps track trends that may indicate disease progression. A single mildly elevated reading often has a benign explanation — trending over multiple years is more informative than any single value.
FIB-4 index: Calculated from age, ALT, AST, and platelet count, the FIB-4 score is the most widely validated non-invasive fibrosis risk stratification tool for NAFLD. Adults with metabolic risk factors should have FIB-4 calculated at least once; those with intermediate or high scores benefit from specialist referral. A low FIB-4 (<1.30 under age 65; <2.0 age 65+) provides meaningful reassurance about the absence of advanced fibrosis and can guide the interval for repeat testing.
Full metabolic panel and lipid profile: Blood glucose (fasting or HbA1c), lipids, and kidney function all influence liver and digestive health in ways that are often underappreciated. Insulin resistance — reflected in elevated fasting glucose, HbA1c in the prediabetes range, or elevated triglycerides with low HDL — is the key driver of NAFLD progression. Annual metabolic screening identifies these drivers before they compound into significant organ disease.
Complete blood count (CBC): Thrombocytopenia (low platelets) is one of the earliest signs of portal hypertension from cirrhosis. Anaemia in an older adult requires evaluation for iron deficiency, which in this context should prompt consideration of GI blood loss. CBC is typically part of any annual comprehensive blood panel.
Hepatitis B surface antigen (HBsAg) and hepatitis C antibody: These tests need to be done only once if the result is negative and no new exposures have occurred. Adults born between 1945 and 1965 (for HCV birth cohort risk) and those who have never been tested for HBV should have one-time testing. If positive, treatment decisions and surveillance follow specific protocols discussed in our article on liver cancer screening awareness.
Vitamin B12 and vitamin D: B12 deficiency risk increases significantly in adults over 50, particularly those on long-term proton pump inhibitors, and is addressed in the digestive health context in our guide to digestive health after age 60. Vitamin D deficiency affects bone mineral density, immune function, and potentially liver health, with insufficiency common in older adults with limited sun exposure.
Thyroid function (TSH): Hypothyroidism causes constipation, weight gain, and non-alcoholic fatty liver disease through metabolic effects. Annual TSH is particularly relevant for women over 50 and adults with metabolic syndrome. Thyroid disease also interacts with several medications metabolised by the liver.
Section 2: Colorectal Cancer Screening — Stay Current
Colorectal cancer is among the most preventable cancers when screening is current, yet a significant proportion of eligible adults are not up to date. The annual checklist item here is not performing a test every year — it is confirming your current screening is up to date and knowing when the next one is due:
Average-risk adults aged 45–75: Choose one option and track its interval: annual high-sensitivity guaiac FOBT or FIT (stool blood test), Cologuard stool DNA test every 1–3 years, or colonoscopy every 10 years (or 5 years for flexible sigmoidoscopy). A positive FIT or Cologuard always requires follow-up colonoscopy regardless of prior screening history. Our detailed comparison of these options is in the article on stool-based colon cancer screening tests.
Higher-risk adults: Those with a personal or family history of colorectal polyps or colorectal cancer, inflammatory bowel disease, or certain hereditary cancer syndromes (Lynch syndrome, familial adenomatous polyposis) have different — typically shorter — recommended screening intervals. If any of these apply, your specific interval should be guided by your gastroenterologist rather than the average-risk schedule.
Adults aged 76–85: Benefit from continued screening depends on overall health and prior screening history. Discuss the trade-offs with your doctor — a 76-year-old with no prior colonoscopy may still benefit substantially, while an 85-year-old with recent normal colonoscopy may not. Current guidelines recommend an individualised decision rather than a blanket recommendation in this age group.
Section 3: Liver Imaging and Surveillance
Liver ultrasound for NAFLD/NASH monitoring: Adults with confirmed NAFLD or NASH, particularly those with metabolic risk factors (obesity, type 2 diabetes), benefit from periodic abdominal ultrasound to assess liver echogenicity (reflecting fat content) and to check for features suggesting advanced disease. The frequency is typically every 1–3 years depending on fibrosis risk — your gastroenterologist or hepatologist should specify the interval based on your FIB-4 and FibroScan results.
HCC surveillance ultrasound (every 6 months): This is not an annual item — it is a biannual one — but it belongs on the checklist for those who qualify: adults with cirrhosis from any cause, and certain chronic hepatitis B carriers. Each annual review should confirm that the prior six months of surveillance was completed and the next ultrasound is scheduled. Gaps in surveillance are common and have real consequences for early detection. Our full guide to surveillance eligibility is in the article on liver cancer screening awareness.
FibroScan (liver stiffness measurement): FibroScan is non-invasive and provides a reliable estimate of liver fibrosis. It is recommended for adults with intermediate or elevated FIB-4 scores who do not have confirmed cirrhosis, to better characterise fibrosis stage and guide management decisions. FibroScan does not need to be repeated annually — typically every 2–3 years or when clinical circumstances change is appropriate.
Section 4: Upper GI Surveillance
Barrett’s esophagus screening: Adults with chronic weekly GERD symptoms for five or more years plus additional risk factors (male sex, obesity, age over 50, smoking history, white ethnicity) meet criteria for a one-time upper endoscopy to screen for Barrett’s esophagus. If Barrett’s is found, surveillance endoscopy intervals are set by the degree of dysplasia (typically every 3–5 years for non-dysplastic Barrett’s). Annual checklist item: confirm whether you have had this evaluation if you meet the criteria.
H. pylori status: Helicobacter pylori infection causes peptic ulcer disease and significantly increases gastric cancer risk. Adults with unexplained iron-deficiency anaemia, chronic dyspepsia, or gastric ulcer history who have not been tested and treated for H. pylori should be. Testing is a simple breath test or stool antigen test. Eradication reduces ulcer recurrence, reduces gastric cancer risk, and improves symptoms in a proportion of those with functional dyspepsia. Annual checklist item: confirm H. pylori status and treatment if previously untested.
Endoscopy for established IBD: Adults with Crohn’s disease or ulcerative colitis have a higher risk of colorectal dysplasia after 8–10 years of disease duration and require IBD surveillance colonoscopy at specific intervals guided by their gastroenterologist — typically every 1–3 years depending on disease extent and activity. Annual checklist item: confirm that the next IBD surveillance colonoscopy is scheduled.
Section 5: Medication and Supplement Review
An annual medication review specifically focused on liver and digestive health is a high-yield but underutilised checklist item. The practical questions to review annually:
- Are any of my current medications hepatotoxic, and is the benefit-risk balance still appropriate?
- Have any new medications been added this year that interact with existing medications via CYP3A4 or other hepatic pathways?
- Am I taking any supplements without my doctor’s knowledge? Herbal products in particular can cause drug-induced liver injury, and disclosure is important if liver enzymes are monitored.
- If I take NSAIDs regularly, is gastroprotective co-therapy (a PPI) in place to reduce gastric ulcer risk?
- If I take long-term PPIs, have liver enzyme changes, B12 status, and magnesium been checked in the past 12 months?
The LiverTox database (NIH) provides detailed hepatotoxicity profiles for specific medications and supplements and is available to patients and clinicians. Our article on supplements for digestive health covers the evidence and safety considerations for common digestive supplements.
Section 6: Lifestyle and Symptom Self-Assessment
Annual checklist items that do not require a clinical test but require honest self-assessment:
Alcohol consumption: Count actual weekly units and compare against recommended limits. The NIAAA defines heavy drinking as more than 14 drinks per week for men or 7 for women. Adults over 60 should apply lower thresholds than standard adult guidelines, given reduced hepatic metabolism with age. Any consumption alongside hepatotoxic medications deserves discussion with a doctor.
Body weight and waist circumference: Track trends rather than single values. Increasing central adiposity (waist circumference >94 cm in men, >80 cm in women) is the most hepatologically relevant obesity measure, as visceral fat is more directly linked to NAFLD than subcutaneous fat. Five percent or more unintentional weight loss over 3–6 months warrants medical evaluation regardless of starting weight.
Bowel habit review: Changes in bowel habit lasting more than three weeks — new constipation, new loose stools, pencil-thin stools, or any rectal bleeding — should prompt a doctor’s visit rather than watchful waiting. Most changes have benign explanations but bowel habit change is a key colorectal cancer symptom and should not be self-managed without evaluation.
Symptom review: Annual self-check for new or worsening dyspepsia (upper abdominal discomfort with meals), difficulty swallowing, heartburn frequency, and any jaundice, dark urine, or pale stools. Persistent symptoms that have not been evaluated are the item most likely to be deferred — and most likely to matter.
Section 7: Vaccinations Relevant to Liver Health
Vaccination is an overlooked component of liver health maintenance. Annual checklist review of vaccination status for hepatitis A and B is particularly relevant for adults whose status may not have been reviewed in years:
Hepatitis A vaccine: Hepatitis A vaccination is recommended for adults with chronic liver disease of any cause — acute hepatitis A superimposed on pre-existing liver disease causes disproportionately severe outcomes and higher mortality than in otherwise healthy adults. Two doses provide long-term protection. Most adults over 50 were not vaccinated in childhood and should confirm their status.
Hepatitis B vaccine: The three-dose hepatitis B vaccine series is recommended for all unvaccinated adults under 60 (and is recommended for adults 60+ on an individual decision basis). Adults with chronic liver disease, diabetes, or chronic kidney disease who have not been vaccinated or whose immunity has not been confirmed (anti-HBs titre ≥10 mIU/mL) should discuss completing the series with their doctor.
COVID-19 and influenza: Both severe respiratory illnesses can worsen outcomes in adults with chronic liver disease, particularly cirrhosis, through haemodynamic stress and systemic inflammation. Annual influenza vaccination and up-to-date COVID-19 vaccination are standard recommendations for adults with chronic liver conditions.
Annual checklist item: confirm hepatitis A and B vaccination status. If vaccinated but with chronic liver disease, confirm anti-HBs titre is protective. For the broader digestive health and liver supplement context, our guide to liver health after age 60 covers the full landscape of liver-specific risks and management in older adults.
Annual Liver and Digestive Health Checklist — Quick Reference
Blood tests (annually):
- Liver enzymes: ALT, AST, ALP, GGT ✓
- FIB-4 score (if metabolic risk factors present) ✓
- Fasting glucose / HbA1c, lipids, CBC ✓
- Hepatitis B and C status (once if unknown) ✓
- Vitamin B12 (especially if on long-term PPI) ✓
Screening (confirm interval is current):
- Colorectal cancer: FIT/FOBT annually, Cologuard q1–3yr, or colonoscopy q10yr ✓
- HCC ultrasound every 6 months (cirrhosis / qualifying HBV) ✓
- Barrett’s esophagus endoscopy: once if chronic GERD + risk factors ✓
Annual self-assessment:
- Alcohol intake, waist circumference, symptom changes ✓
- Medication and supplement review for hepatotoxic interactions ✓
Do not defer these symptoms to the next annual check: Jaundice (yellowing of skin or eyes), vomiting blood, black or tarry stools, new rectal bleeding, unexplained weight loss of >5% in 3 months, severe abdominal pain, or swollen abdomen. These require prompt evaluation — not an annual appointment.
Frequently Asked Questions
Do I need all of these tests if I feel completely well?
That is precisely the point of the checklist — most liver and digestive diseases do not cause symptoms until they are advanced. Feeling well does not exclude early NAFLD, pre-cirrhotic fibrosis, a small colorectal polyp, or Barrett’s esophagus. The tests that matter most for you depend on your individual risk factors: someone with type 2 diabetes, obesity, and a family history of colorectal cancer has a different highest-priority checklist than a lean 45-year-old with no family history. The value of the checklist is not that every adult needs every test every year — it is that each adult can identify which items apply to them and ensure those are current.
Can my GP order all of these tests, or do I need specialist referrals?
Most items on this checklist can be ordered and managed by a GP: annual blood tests including liver enzymes, metabolic panel, CBC, and B12; FIT stool testing; one-time hepatitis B and C testing; H. pylori testing; and lifestyle assessment. Colonoscopy requires a gastroenterology referral and scheduling. Barrett’s esophagus screening upper endoscopy requires gastroenterology referral. HCC surveillance ultrasound can be ordered by a GP but is often most reliably delivered through a structured programme managed by a hepatologist or gastroenterologist. FibroScan is a specialist test. A GP who is aware of your risk profile can coordinate most of these referrals — the checklist works best when you bring it to your annual GP appointment and ask specifically which items apply to you.
What is FIB-4 and how do I calculate mine?
FIB-4 is a non-invasive fibrosis risk score calculated from four values available on standard blood tests: age (years), AST (units/L), ALT (units/L), and platelet count (×10⁹/L). The formula is: FIB-4 = (Age × AST) ÷ (Platelets × √ALT). Online calculators are freely available — search “FIB-4 calculator” and enter your most recent blood test values. A score below 1.30 (or 2.0 in adults over 65) suggests low probability of advanced fibrosis and typically means annual monitoring with repeat FIB-4 every 1–2 years is sufficient. A score above 2.67 (or 3.25 in adults over 65) suggests higher risk and warrants FibroScan or specialist hepatology evaluation. An intermediate score (between cutoffs) often prompts FibroScan as the next step. Your GP can calculate this from your blood test results and interpret it in your clinical context.
I had a colonoscopy five years ago and it was normal — do I need another one soon?
A normal colonoscopy (no polyps found) in an average-risk adult provides reassurance for 10 years, and the next colonoscopy is due at 10 years from the procedure date. If small adenomatous polyps were found and removed, the recommended surveillance interval is typically 3–5 years depending on the number and characteristics of the polyps. If advanced adenomas (larger than 1 cm, or with high-grade dysplasia, or villous features) were found, the interval is typically 3 years. If you do not know what the colonoscopy found, your gastroenterology practice will have the report — contact them for a copy and ask when the recommended repeat interval is. Not knowing your polyp status means not knowing your current interval recommendation.
My liver enzymes were slightly elevated last year and my doctor said to recheck in six months. They normalised — do I still need to track them?
Normalisation of liver enzymes after a transient elevation with a clear reversible cause (a new medication that was changed, an episode of heavy alcohol use, a viral illness) is generally reassuring. However, in the context of metabolic risk factors — obesity, type 2 diabetes, or metabolic syndrome — transient normalisation does not reliably exclude underlying NAFLD with ongoing fibrosis risk. Annual monitoring of liver enzymes and periodic FIB-4 calculation remains appropriate if metabolic risk factors are present, even when individual readings are normal. The goal is trend tracking over years rather than reacting to individual values.
Is there a single test that covers all liver health monitoring?
No single test captures all aspects of liver health. Liver enzyme tests reflect cell injury but not fibrosis or functional reserve. FIB-4 assesses fibrosis risk but not inflammation or early steatosis. Ultrasound identifies fat and nodules but has limited sensitivity for early fibrosis. FibroScan measures fibrosis accurately but is a specialist procedure. AFP can flag some HCC cases but has significant false-negative and false-positive rates. Each test answers a different question, and a comprehensive assessment uses them together based on what is most relevant for an individual’s risk profile. This is why a structured annual checklist — rather than a single “liver blood test” — better captures the full picture of liver and digestive health monitoring.
References
- Singal AG, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78(6):1922-1965.
- Davidson KW, et al. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA. 2021;325(19):1965-1977. Link
- Chalasani N, et al. The diagnosis and management of nonalcoholic fatty liver disease. Hepatology. 2018;67(1):328-357.
- Shah AG, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clinical Gastroenterology and Hepatology. 2009;7(10):1104-1112.
- Shaheen NJ, et al. ACG Clinical Guideline: Diagnosis and management of Barrett’s esophagus. American Journal of Gastroenterology. 2016;111(1):30-50.
Your FIB-4 explanation was exactly what I needed. My GP mentioned my FIB-4 score at an appointment last year and I had no idea what it meant — I left without understanding whether I should be concerned. Looking back at my bloodwork I can now calculate it myself: age 62, AST 34, ALT 29, platelets 198. Using your formula that gives me approximately (62 × 34) ÷ (198 × √29) = 2108 ÷ 1066 ≈ 1.98. Your article says the cutoff for adults over 65 is 2.0 for low risk, but I’m 62 — so the standard cutoff of 1.30 applies and 1.98 is in the intermediate zone. I now understand that this means I should probably have a FibroScan rather than just annual blood tests, which my GP had not mentioned. I’m going to bring this calculation to my next appointment and ask specifically about FibroScan referral. Thank you for explaining this in a way I could actually use.
Your FIB-4 calculation is correct, and your interpretation is right. For adults under 65, the EASL/AASLD-endorsed thresholds are: below 1.30 = low fibrosis risk (can be monitored with annual blood tests), 1.30–2.67 = indeterminate (FibroScan or specialist referral recommended), above 2.67 = high fibrosis risk (specialist referral). At 1.98, you are in the indeterminate zone, and a FibroScan (transient elastography) would be the standard next step to clarify whether this represents early fibrosis or a normal variant. FibroScan is quick (15 minutes, non-invasive, no preparation needed) and provides a liver stiffness measurement in kPa — readings below 7–8 kPa are generally reassuring, while readings above 10–12 kPa suggest significant fibrosis. Taking your calculated score to your GP and asking specifically about FibroScan referral is exactly the right approach. For context, the intermediate zone contains many people who ultimately have no significant fibrosis — but clarifying this with FibroScan is better than leaving it uncharacterised. The FIB-4 was primarily validated in hepatitis C and NAFLD populations; it performs well as a screening tool but FibroScan remains the preferred confirmatory step when the score is indeterminate.
The vaccination section was something I had never seen on a liver health page before, and it’s genuinely important. I have NAFLD and early fibrosis — I’ve been followed by a hepatologist for three years — and I only learned about the hepatitis A vaccination recommendation for people with liver disease when I specifically asked about it after reading an article similar to this one. My hepatologist confirmed I should have it but it had never come up in three years of appointments. I think the practical issue is that specialist appointments focus on the specialist concern (liver fibrosis progression, medication review) and vaccination status falls between specialties. I’ve now had both doses of hepatitis A and confirmed my hepatitis B immunity. I’d encourage anyone with any chronic liver condition to specifically ask about hepatitis A and B vaccination status at their next appointment — it takes five seconds to ask.